Differential diagnosis and clinical relevance of ovarian carcinoma subtypes

Expert Review of Obstetrics and Gynecology

Volumn 8, Issue 1, 2013, Pages 67-82

  Conklin, Chris M J ^a   Gilks, C Blake ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

clear cell carcinoma; endometrioid carcinoma; mucinous carcinoma; ovarian surface epithelial carcinoma; serous carcinoma

Indexed keywords

AROMATASE INHIBITOR; BAZEDOXIFENE; BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SELUMETINIB; TAMOXIFEN; TRANSCRIPTION FACTOR CDX2;

BETA CATENIN GENE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COLLOID CARCINOMA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; ENDOMETRIOID CARCINOMA; GENE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; ONCOGENE K RAS; OVARY CARCINOMA; PTEN GENE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84871991450     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/eog.12.72     Document Type: Review

References (135)

1. Coleman MP, Forman D, Bryant H et al.; ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): An analysis of populationbased cancer registry data. Lancet 377(9760), 127-138 (2011).
2. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: The size of the problem. Best Pract. Res. Clin. Obstet. Gynaecol. 20(2), 207-225 (2006). (Pubitemid 43380597)
3. Anttila A, Ronco G, Clifford G et al. Cervical cancer screening programmes and policies in 18 European countries. Br. J. Cancer 91(5), 935-941 (2004). (Pubitemid 39273788)
4. Prat J. Pathology of the Ovary. WB Saunders Co., PA, USA (2004).
5. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Int. J. Gynecol. Pathol. 18(3), 288 (1999).
6. Walker JL. Intraperitoneal chemotherapy for epithelial ovarian cancer. Presented at: 2009 ASCO Meeting. FL, USA, 29 May Y 2 June 2009.
7. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev. 1, CD005340 (2006)
8. Perren TJ, Swart AM, Pfisterer JA et al.; ICON7 Investigators. A Phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365(26), 2484-2496 (2011).
9. Burger RA, Brady MF, Bookman MA et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365(26), 2473-2483 (2011).
10. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am. J. Surg. Pathol. 34(3), 433-443 (2010).
11. Folkins AK, Jarboe EA, Saleemuddin A et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 109(2), 168-173 (2008).
12. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin. Med. Res. 5(1), 35-44 (2007). (Pubitemid 350218778)
13. Folkins AK, Jarboe EA, Roh MH, Crum CP. Precursors to pelvic serous carcinoma and their clinical implications. Gynecol. Oncol. 113(3), 391-396 (2009).
14. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 195(4), 451-456 (2001). (Pubitemid 33069670)
15. McMeekin DS, Burger RA, Manetta A, DiSaia P, Berman ML. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol. Oncol. 59(1), 81-86 (1995).
16. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer. Obstet. Gynecol. 100(4), 788-795 (2002). (Pubitemid 35300039)
17. Schmeler KM, Gershenson DM. Lowgrade serous ovarian cancer: A unique disease. Curr. Oncol. Rep. 10(6), 519-523 (2008).
18. Kobel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev. Mol. Med. 10, e22 (2008)
19. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: Recent advances. Hum. Pathol. 40(9), 1213-1223 (2009).
20. Trimble EL, Fountain J, Birrer MJ. Recommendations of the 2005 ovarian cancer state of the science meeting. Gynecologic Oncol. 103(2), S26 (2006)
21. Cramer SF, Roth LM, Ulbright TM et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch. Pathol. Lab. Med. 111(9), 819-829 (1987). (Pubitemid 17121987)
22. Sakamoto A, Sasaki H, Furusato M et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol. Oncol. 54(1), 54-58 (1994). (Pubitemid 24239408)
23. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathological evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS 99(4), 353-358 (1991).
24. Hernandez E, Bhagavan BS, Parmley TH, Rosenshein NB. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol. Oncol. 17(1), 117-123 (1984). (Pubitemid 14176297)
25. Kobel M, Kalloger SE, Baker PM et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study. Am. J. Surg. Pathol. 34(7), 984-993 (2010).
26. Gilks CB, Ionescu DN, Kalloger SE et al.; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum. Pathol. 39(8), 1239-1251 (2008).
27. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am. J. Pathol. 160(4), 1223-1228 (2002). (Pubitemid 34411626)
28. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv. Anat. Pathol. 16(5), 267-282 (2009).
29. Singer G, Oldt R 3rd, Cohen Y et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95(6), 484-486 (2003). (Pubitemid 36432423)
30. Singer G, Shih IeM, Truskinovsky A, Umudum H, Kurman RJ. Mutational analysis of KRAS segregates ovarian serous carcinomas into two types: Invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int. J. Gynecol. Pathol. 22(1), 37-41 (2003). (Pubitemid 36014274)
31. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IeM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 64(19), 6915-6918 (2004). (Pubitemid 39330999)
32. Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221(1), 49-56 (2010).
33. Press JZ, De Luca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8, 17 (2008).
34. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23(1), 41-44 (2004). (Pubitemid 38018236)
35. Malpica A, Deavers MT, Lu K et al. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 28(4), 496-504 (2004). (Pubitemid 38436523)
36. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68(3), 700-710 (2001). (Pubitemid 32203724)
37. Kobel M, Kalloger SE, Huntsman DG et al.; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 29(3), 203-211 (2010).
38. Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih IeM. Shortened telomeres in serous tubal intraepithelial carcinoma: An early event in ovarian high-grade serous carcinogenesis. Am. J. Surg. Pathol. 34(6), 829-836 (2010).
39. Malpica A, Deavers MT, Tornos C et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am. J. Surg. Pathol. 31(8), 1168-1174 (2007). (Pubitemid 47207118)
40. Schrader KA, Hurlburt J, Kalloger SE et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: Utility of a histology-based referral strategy. Obstet. Gynecol. 120(2 Pt 1), 235-240 (2012).
41. Shaw PA, McLaughlin JR, Zweemer RP et al. Histopathologic features of genetically determined ovarian cancer. Int. J. Gynecol. Pathol. 21(4), 407-411 (2002).
42. Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
43. Kobel M, Kalloger SE, Boyd N et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 5(12), e232 (2008)
44. AlHussaini M, Stockman A, Foster H, McCluggage WG. WT1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44(2), 109-115 (2004). (Pubitemid 38296970)
45. Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 44(2), 109-115 (2004). (Pubitemid 38296970)
46. Han G, Gilks CB, Leung S et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of highgrade serous carcinoma: An interobserver correlative and immunohistochemical study of 32 cases. Am. J. Surg. Pathol. 32(7), 955-964 (2008).
47. Kobel M, Kalloger SE, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am. J. Surg. Pathol. 33(1), 14-21 (2009).
48. Vergote I, Trope CG, Amant F et al.; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363(10), 943-953 (2010).
49. Kortmann U, McAlpine JN, Xue H et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. 17(4), 783-791 (2011).
50. Gershenson DM, Sun CC, Lu KH et al. Clinical behavior of stage IIYIV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 108(2), 361-368 (2006). (Pubitemid 44305678)
51. Oza AM, Cibula D, Oakn1in A et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinumsensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label Phase II study. J. Clin. Oncol. 30(Suppl.) Abstract 5001 (2012).
52. Bell DA, Longacre TA, Prat J et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: Workshop perspectives. Hum. Pathol. 35(8), 934-948 (2004). (Pubitemid 39037177)
53. Parker RL, Clement PB, Chercover DJ, Sornarajah T, Gilks CB. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: A report of two cases. Int. J. Gynecol. Pathol. 23(3), 265-272 (2004). (Pubitemid 38857115)
54. Dehari R, Kurman RJ, Logani S, Shih IeM. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: A morphologic and molecular genetic analysis. Am. J. Surg. Pathol. 31(7), 1007-1012 (2007). (Pubitemid 47012296)
55. Armes JE, Lourie R, de Silva M et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int. J. Gynecol. Pathol. 24(4), 363-368 (2005). (Pubitemid 41368290)
56. Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol. Oncol. 103(3), 883-887 (2006). (Pubitemid 44821309)
57. Sieben NL, Macropoulos P, Roemen GM et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 202(3), 336-340 (2004). (Pubitemid 38325243)
58. Crispens MA, Bodurka D, Deavers M, Lu K, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet. Gynecol. 99(1), 3-10 (2002). (Pubitemid 34075460)
59. Buckanovich RJ, Berger R, Sella A, Sikic BI, Shen X, Ramies DA. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a Phase II randomized discontinuation trial (RDT). J. Clin. Oncol. 29, S15 (2011).
60. Jones S, Wang TL, Kurman RJ et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J. Pathol. 226(3), 413-420 (2012).
61. Koonings PP, Campbell K, Mishell DR Jr, Grimes DA. Relative frequency of primary ovarian neoplasms: A 10-year review. Obstet. Gynecol. 74(6), 921-926 (1989). (Pubitemid 20003288)
62. Naik JD, Seligmann J, Perren TJ. Mucinous tumours of the ovary. J. Clin. Pathol. 65(7), 580-584 (2012).
63. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: Incidence in routine practice with a new approach to improve intraoperative diagnosis. Am. J. Surg. Pathol. 27(7), 985-993 (2003). (Pubitemid 36763545)
64. Ludwick C, Gilks CB, Miller D, Yaziji H, Clement PB. Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: A report of four cases and review of the literature. Int. J. Gynecol. Pathol. 24(3), 205-217 (2005). (Pubitemid 40885072)
65. Shimada M, Kigawa J, Ohishi Y et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol. Oncol. 113(3), 331-334 (2009).
66. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J. Clin. Oncol. 22(6), 1040-1044 (2004). (Pubitemid 41095036)
67. Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 31(5), 1031-1045 (1973).
68. Watkin W, Silva EG, Gershenson DM. Mucinous carcinoma of the ovary. Pathologic prognostic factors. Cancer 69(1), 208-212 (1992).
69. de Nictolis M, Montironi R, Tommasoni S et al. Benign, borderline, and well-differentiated malignant intestinal mucinous tumors of the ovary: A clinicopathologic, histochemical, immunohistochemical, and nuclear quantitative study of 57 cases. Int. J. Gynecol. Pathol. 13(1), 10-21 (1994). (Pubitemid 24006329)
70. Lee KR, Scully RE. Mucinous tumors of the ovary: A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am. J. Surg. Pathol. 24(11), 1447-1464 (2000).
71. Rodriguez IM, Prat J. Mucinous tumors of the ovary: A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am. J. Surg. Pathol. 26(2), 139-152 (2002). (Pubitemid 34127494)
72. Provenza C, Young RH, Prat J. Anaplastic carcinoma in mucinous ovarian tumors: A clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules. Am. J. Surg. Pathol. 32(3), 383-389 (2008). (Pubitemid 351398929)
73. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. KRAS mutations in mucinous ovarian tumors: A clinicopathologic and molecular study of 95 cases. Cancer 79(8), 1581-1586 (1997). (Pubitemid 27154791)
74. Gemignani ML, Schlaerth AC, Bogomolniy F et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol. Oncol. 90(2), 378-381 (2003). (Pubitemid 36952030)
75. McCaughan H, Um I, Langdon SP, Harrison DJ, Faratian D. HER2 expression in ovarian carcinoma: Caution and complexity in biomarker analysis. J. Clin. Pathol. 65(7), 670-671; author reply 671 (2012).
76. McAlpine JN, Wiegand KC, Vang R et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9, 433 (2009)
77. Lin WL, Kuo WH, Chen FL et al. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer. Ann. Surg. Oncol. 18(8), 2388-2394 (2011).
78. Anglesio M, Kommoss S, Tolcher M et al. Molecular characterization of mucinous ovarian tumors supports a stratified treatment approach with HER2 targeting in 18% of carcinomas. J. Pathol. doi:10.1002/path.4088 (2012) (Epub ahead of print).
79. Park SY, Kim HS, Hong EK, Kim WH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum. Pathol. 33(11), 1078-1085 (2002). (Pubitemid 35416704)
80. Vang R, Gown AM, Wu LS et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: Comparison with CK20 and correlation with coordinate expression of CK7. Mod. Pathol. 19(11), 1421-1428 (2006). (Pubitemid 44624160)
81. Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int. J. Gynecol. Pathol. 21(4), 391-400 (2002).
82. Ronnett BM, Yemelyanova AV, Vang R et al. Endocervical adenocarcinomas with ovarian metastases: Analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am. J. Surg. Pathol. 32(12), 1835-1853 (2008).
83. Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol. Oncol. 97(2), 436-441 (2005). (Pubitemid 40614887)
84. Sundar S, Symonds RP, Decatris MP et al. Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol. Oncol. 94(2), 502-508 (2004). (Pubitemid 39024560)
85. Shimizu Y, Umezawa S, Hasumi K. A Phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann. Acad. Med. Singap. 27(5), 650-656 (1998). (Pubitemid 29037230)
86. Leitao MM Jr, Boyd J, Hummer A et al. Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am. J. Surg. Pathol. 28(2), 147-159 (2004). (Pubitemid 38124722)
87. Schwartz DR, Kardia SL, Shedden KA et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62(16), 4722-4729 (2002).
88. Falkenberry SS, Steinhoff MM, Gordinier M, Rappoport S, Gajewski W, Granai CO. Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases. J. Reprod. Med. 41(10), 713-718 (1996). (Pubitemid 26367554)
89. Irving JA, Catasus L, Gallardo A et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: Alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum. Pathol. 36(6), 605-619 (2005). (Pubitemid 40922566)
90. Brescia RJ, Dubin N, Demopoulos RI. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival. Int. J. Gynecol. Pathol. 8(2), 132-138 (1989). (Pubitemid 19116249)
91. Kline RC, Wharton JT, Atkinson EN, Burke TW, Gershenson DM, Edwards CL. Endometrioid carcinoma of the ovary: Retrospective review of 145 cases. Gynecol. Oncol. 39(3), 337-346 (1990).
92. Russell P. The pathological assessment of ovarian neoplasms. II: The proliferating 'epithelial' tumours. Pathology 11(2), 251-282 (1979). (Pubitemid 9229175)
93. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75(1), 81-86 (1995).
94. Young RH, Prat J, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. A clinicopathological analysis of 13 cases. Am. J. Surg. Pathol. 6(6), 513-522 (1982). (Pubitemid 12029443)
95. Roth LM, Liban E, Czernobilsky B. Ovarian endometrioid tumors mimicking Sertoli and SertoliYLeydig cell tumors: Sertoliform variant of endometrioid carcinoma. Cancer 50(7), 1322-1331 (1982). (Pubitemid 12031956)
96. Pitman MB, Young RH, Clement PB, Dickersin GR, Scully RE. Endometrioid carcinoma of the ovary and endometrium, oxyphilic cell type: A report of nine cases. Int. J. Gynecol. Pathol. 13(4), 290-301 (1994). (Pubitemid 24309716)
97. Catasus L, Bussaglia E, Rodrguez I et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: Similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol. 35(11), 1360-1368 (2004). (Pubitemid 39601576)
98. Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 58(7), 1344-1347 (1998). (Pubitemid 28193586)
99. Romero IL, Lee W, Mitra AK et al. The effects of 17b-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol. Oncol. 124(1), 134-141 (2012).
100. Hampel H, Stephens JA, Pukkala E et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: Later age of onset. Gastroenterology 129(2), 415-421 (2005). (Pubitemid 41096629)
101. Deavers MT, Malpica A, Liu J, Broaddus R, Silva EG. Ovarian sex cord-stromal tumors: An immunohistochemical study including a comparison of calretinin and inhibin. Mod. Pathol. 16(6), 584-590 (2003). (Pubitemid 36718440)
102. Matias-Guiu X, Pons C, Prat J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum. Pathol. 29(8), 840-845 (1998). (Pubitemid 28375991)
103. Aguirre P, Thor AD, Scully RE. Ovarian endometrioid carcinomas resembling sex cord-stromal tumors. An immunohistochemical study. Int. J. Gynecol. Pathol. 8(4), 364-373 (1989). (Pubitemid 19260744)
104. Groisman GM, Meir A, Sabo E. The value of CDX2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Int. J. Gynecol. Pathol. 23(1), 52-57 (2004). (Pubitemid 38018238)
105. Vang R, Gown AM, Farinola M et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: Utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am. J. Surg. Pathol. 31(5), 653 (2007).
106. Storey DJ, Rush R, Stewart M et al. Endometrioid epithelial ovarian cancer: 20 years of prospectively collected data from a single center. Cancer 112(10), 2211-2220 (2008). (Pubitemid 351628631)
107. Bowman A, Gabra H, Langdon SP et al. CA125 response is associated with estrogen receptor expression in a Phase II trial of letrozole in ovarian cancer. Clin. Cancer Res. 8(7), 2233-2239 (2002). (Pubitemid 34753595)
108. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: Is there a role? Int. J. Gynecol. Cancer 18(4), 600-614 (2008). (Pubitemid 352020164)
109. Smyth JF, Gourley C, Walker G et al. Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 13(12), 3617-3622 (2007). (Pubitemid 46955124)
110. Weichert W, Denkert C, Noske A et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia 10(9), 1021-1027 (2008).
111. Takai N, Narahara H. Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr. Med. Chem. 14(24), 2548-2553 (2007). (Pubitemid 350018467)
112. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88(11), 2584-2589 (2000). (Pubitemid 30331967)
113. Mizuno M, Kikkawa F, Shibata K et al. Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J. Surg. Oncol. 94(2), 138-143 (2006). (Pubitemid 44267195)
114. Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol. Oncol. 70(2), 255-258 (1998). (Pubitemid 28430939)
115. Tsunematsu R, Saito T, Iguchi H, Fukuda T, Tsukamoto N. Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: Case report. Gynecol. Oncol. 76(2), 218-222 (2000). (Pubitemid 30067199)
116. Recio FO, Piver MS, Hempling RE, Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78(10), 2157-2163 (1996). (Pubitemid 26367609)
117. Mandai M, Yamaguchi K, Matsumura N, Baba T, Konishi I. Ovarian cancer in endometriosis: Molecular biology, pathology, and clinical management. Int. J. Clin. Oncol. 14(5), 383-391 (2009).
118. Kobayashi H. Ovarian cancer in endometriosis: Epidemiology, natural history, and clinical diagnosis. Int. J. Clin. Oncol. 14(5), 378-382 (2009).
119. Ballouk F, Ross JS, Wolf BC. Ovarian endometriotic cysts. An analysis of cytologic atypia and DNA ploidy patterns. Am. J. Clin. Pathol. 102(4), 415-419 (1994). (Pubitemid 24323332)
120. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet. Gynecol. 100(2), 281-287 (2002). (Pubitemid 34874791)
121. Sangoi AR, Soslow RA, Teng NN, Longacre TA. Ovarian clear cell carcinoma with papillary features: A potential mimic of serous tumor of low malignant potential. Am. J. Surg. Pathol. 32(2), 269-274 (2008). (Pubitemid 351172142)
122. Silva EG, Young RH. Endometrioid neoplasms with clear cells: A report of 21 cases in which the alteration is not of typical secretory type. Am. J. Surg. Pathol. 31(8), 1203-1208 (2007). (Pubitemid 47207124)
123. Otsuka J, Okuda T, Sekizawa A et al. KRAS mutation may promote carcinogenesis of endometriosis leading to ovarian clear cell carcinoma. Med. Electron Microsc. 37(3), 188-192 (2004). (Pubitemid 40576037)
124. Jensen KC, Mariappan MR, Putcha GV et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am. J. Surg. Pathol. 32(7), 1029-1037 (2008).
125. Cai KQ, Albarracin C, Rosen D et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum. Pathol. 35(5), 552-559 (2004). (Pubitemid 38656938)
126. Kuo KT, Mao TL, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 174(5), 1597-1601 (2009).
127. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363(16), 1532-1543 (2010).
128. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1b) in clear cell tumors and endometriosis of the ovary. Mod. Pathol. 19(1), 83-89 (2006). (Pubitemid 43250982)
129. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15(1), 10-17 (1983). (Pubitemid 13194678)
130. Pectasides D, Fountzilas G, Aravantinos G et al. Advanced stage clear-cell epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol. Oncol. 102(2), 285-291 (2006). (Pubitemid 44041640)
131. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT-1) in epithelial ovarian tumors. Int. J. Gynecol. Pathol. 19(2), 158 (2000).
132. Goff BA, Sainz de la Cuesta R, Muntz HG et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol. Oncol. 60(3), 412-417 (1996). (Pubitemid 26077628)
133. Nagai Y, Inamine M, Hirakawa M et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol. Oncol. 107(3), 469-473 (2007). (Pubitemid 350160858)
134. Hoskins PJ, Le N, Gilks B et al. Low-stage ovarian clear cell carcinoma: Populationbased outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J. Clin. Oncol. 30(14), 1656-1662 (2012).
135. Molckovsky A, Siu LL. First-in-class, first-in-human Phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol. 1, 20 (2008).